HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR)

Atyr PHARMA (NASDAQ:ATYR)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $35.00 target price on the stock.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company started coverage on shares of Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 price target on shares of Atyr PHARMA in a research report on Wednesday, August 14th. Finally, Jefferies Financial Group started coverage on shares of Atyr PHARMA in a research report on Thursday, September 5th. They issued a “buy” rating and a $9.00 price target for the company.

Atyr PHARMA Stock Performance

Shares of Atyr PHARMA stock opened at $3.33 on Tuesday. The firm has a fifty day moving average of $2.85. Atyr PHARMA has a 12-month low of $1.14 and a 12-month high of $3.80. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The firm has a market cap of $279.52 million, a PE ratio of -3.54 and a beta of 1.07.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, analysts forecast that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.